Guaifenesin + Salbutamol (Ventar EXP) 50 mg/1 mg per 5 mL Syrup appeared in clear red color and Strawberry flavor.
Each 5 mL (1 teaspoonful) contains: Guaifenesin, USP 50 mg, Salbutamol 1 mg (equivalent to 1.20 mg Salbutamol sulfate).
Pharmacology: Pharmacodynamics: Salbutamol is a selective Beta-2 adrenoceptor agonist. At therapeutic doses, it acts on the Beta-2 adrenoceptors of bronchial muscle, with little or no action on the Beta-1 adrenoceptors of cardiac muscle. Guaifenesin can make the viscous mucus of the respiratory pathway more fluid and therefore expectoration and reduces cough.
Pharmacokinetics: Salbutamol is absorbed from the gastrointestinal tract and undergoes considerable first-pass metabolism to the phenolic sulfate. Both unchanged drug and conjugate are excreted primarily in the urine. The bioavailability of orally administered salbutamol is about 50%.
Guaifenesin is well-absorbed after oral administration. After the administration of guaifenesin 600 mg in healthy adult volunteers, the maximum peak plasma concentration (Cmax) was approx 1.4 mcg/mL with Tmax about 15 minutes after drug administration.
Respiratory disorders complicated by bronchospasm and excessive secretion of tenacious mucus, bronchial asthma, chronic bronchitis and emphysema.
Children: 2-6 years old: 1 teaspoonful (5 mL) three or four times daily.
6-12 years old: 2 teaspoonful (10 mL) three or four times daily.
Adults: 2-4 teaspoonfuls (10-20 mL) two or three times daily.
Or as prescribed by the physician.
Overdosage with the use of salbutamol have generally only described the features that may be expected with beta-2 agonists such as tachycardia, CNS stimulation, tremor, hypokalemia, and hyperglycemia. The use of activated charcoal may be considered after oral overdose in patients who have taken a potentially toxic amount and present within 1 hour.
Contraindicated to patients with known hypersensitivity to salbutamol sulfate, guaifenesin (Ventar EXP).
The management of asthma involves prophylactic measures to reduce inflammation and airway resistance and to maintain airflow and specific regimens for the treatment of acute attacks. Lung function measurement is important in determining treatment thus, peak flow monitoring is encouraged. If usual relief is diminished or the duration of action is reduced, patients are warned not to increase the dose or frequency of administration but seek medical advice. Salbutamol should be given with caution in hyperthyroidism, myocardial insufficiency, arrhythmias, susceptibility to QT-interval prolongation, hypertension and diabetes mellitus. In severe asthma, particular precaution is required to avoid inducing hypokalemia as this effect may be potentiated by hypoxia or by concomitant administration of other anti-asthma drugs. Plasma potassium concentrations should be monitored.
Administration of drugs during pregnancy should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus. During worldwide marketing experience, rare cases of various congenital anomalies, including cleft palate and limb defects have been reported in the offspring of patients being treated with salbutamol. Some of the mothers were taking multiple medications during their pregnancies. Because no consistent pattern of defects can be discerned and baseline rate for congenital anomalies is 2-3%, a relationship with salbutamol use cannot be established. As salbutamol is probably secreted in breast milk, its use in nursing mothers is not recommended unless the expected benefits outweigh any potential risk. It is not known whether salbutamol in breast milk has a harmful effect on the neonate.
Salbutamol may cause fine tremor of skeletal muscle (particularly the hands), palpitations, tachycardia, nervous tension, headaches, peripheral vasodilation and rarely, muscle cramps to some patients. Very rarely, hypersensitivity reactions such as bronchospasm, urticaria, angioedema, hypotension and collapse have been reported with salbutamol. Side effects such as gastrointestinal discomfort, nausea and vomiting have occasionally been reported with guaifenesin, particularly in very large doses.
Use of salbutamol and other beta-2 agonists with corticosteroid, diuretics, or xanthines increases the risk of hypokalemia, and monitoring of potassium concentration is recommended in a severe asthma, where such combination therapy is common.
Store at temperatures not exceeding 30°C.
R05CA10 - combinations ; Belongs to the class of expectorants. Used in the treatment of wet cough.
Ventar EXP syr
60 mL x 1's (P97.88/bottle)
Sign Out
Continue with Google
Sign up with email
Already a member?
Sign in
